-1.png?width=77&height=77&name=Otis%20Johnson%20(1)-1.png)
Otis Johnson
Principal Consultant
Trial Equity
Register for our upcoming webinar
Lorem Ipsum is simply dummy text of the printing and typesetting industry.
Join us as we explore the integration of AI-powered study feasibility within rare indication trials. Discover the unique hurdles faced when conducting trials for rare indications and unravel how AI-driven study feasibility is poised to revolutionize this complex landscape.
Webinar
Thursday, May 23rd 2024
On-Demand
Presented by industry experts Rohit Nambisan from Lokavant, Otis Johnson with Trial Equity, and Mo Ali from Astellas, and Michelle Everill former BMS. This webinar will include:
Whether you're a researcher, clinician, or industry professional, this webinar will offer you valuable perspectives on the future of rare disease research and the pivotal role of AI in driving innovation. Don't miss this opportunity to gain insights, exchange ideas, and be at the forefront of pioneering advancements in rare indication trials.